文献速递神经肿瘤

MRI弥漫表型与WHO 2-3级星形细胞瘤总生存期缩短相关

Association of a diffuse phenotype on MRI with shorter overall survival in patients with astrocytoma CNS WHO grades 2 and 3.
PubMed 文献 · J Neurosurg · 2026-01-30

以T1/T2比值量化MRI弥漫表型,经倾向评分匹配后分析显示,T1/T2比值≤0.33者总生存期显著更短。

要点

  • T1/T2比值可量化星形细胞瘤MRI弥漫表型
  • 匹配后T1/T2比值≤0.33者总生存期显著更短
  • 多因素分析中仅T1/T2比值持续为预后因素

核心结论

  • MRI弥漫表型似与CNS WHO 2级和3级星形细胞瘤患者更短生存期相关。
  • 作者认为该发现值得在前瞻性数据集中进一步研究。

研究设计与样本

  • 回顾性研究,筛选瑞典Sahlgrenska大学医院与德国LMU大学医院2003至2021年间活检诊断的2021 CNS WHO 2级和3级星形细胞瘤患者。
  • 对肿瘤体积进行分割并计算T1/T2比值,采用最近邻1:1倾向评分匹配。

主要发现

  • 未校正分析中,T1/T2比值≤0.33者生存未显著缩短(144 vs 126个月;HR 0.61,95%CI 0.34-1.1;p=0.09)。
  • 倾向评分匹配(Karnofsky功能状态评分、CNS WHO 2021分级、MRI强化、T2肿瘤体积)得到29对,T1/T2比值≤0.33者总生存期显著更短(160 vs 132个月;HR 0.44,95%CI 0.19-1.00;p=0.05)。
  • 多因素分析中仅T1/T2比值持续为预后因素(HR 0.48,95%CI 0.25-0.92;p=0.03)。

关键数值与推荐

  • T1/T2比值定义为T1低信号肿瘤体积与T2高信号肿瘤体积的商。
  • 弥漫表型以T1/T2比值≤0.33界定。

临床怎么用

  • 对未切除的IDH突变型2-3级星形细胞瘤,可计算T1/T2比值辅助评估预后。
  • T1/T2比值低的弥漫表型患者生存可能更短,提示需更密切随访。

局限性

  • 为回顾性研究,作者呼吁在前瞻性数据集中进一步验证。
  • 仅纳入活检未切除患者,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gliomas can appear radiologically diffuse or sharply delineated on MRI. This can be quantified by the T1/T2 ratio, a quotient of the T1 hypointense to T2 hyperintense tumor volume. In patients with CNS WHO grade 2 and 3 isocitrate dehydrogenase (IDH)-mutant astrocytomas, resectability has been shown to be limited in cases of low T1/T2 ratios, that is, in diffusely appearing astrocytomas. The authors set out to investigate if a diffuse phenotype on MRI is associated with overall survival beyond resectability. METHODS: Retrospective data sets from two university hospitals (Sahlgrenska University Hospital, Gothenburg, Sweden; LMU University Hospital, Munich, Germany) were screened for patients diagnosed with 2021 CNS WHO grade 2 and 3 astrocytomas by biopsy between 2003 and 2021. Patients having undergone tumor resection were excluded. Tumor volumes were segmented and the T1/T2 ratio was calculated. Propensity score matching (nearest-neighbor matching, 1:1) was used. RESULTS: One hundred nineteen patients with CNS WHO grade 2 (n = 77, 65%) or grade 3 (n = 42, 35%) IDH-mutant astrocytomas were included in the study. In unadjusted analyses, survival was not significantly shorter in patients with a T1/T2 ratio ≤ 0.33 (144 vs 126 months; HR 0.61, 95% CI 0.34-1.1; p = 0.09). Propensity score matching (Karnofsky Performance Status, CNS WHO 2021 grade, contrast enhancement on MRI, and T2 tumor volume) yielded 29 pairs. Here, significantly shorter overall survival was observed in patients with a T1/T2 ratio ≤ 0.33 (160 vs 132 months; HR 0.44, 95% CI 0.19-1.00; p = 0.05). In multivariate analysis, only the T1/T2 ratio persisted as a prognostic factor (HR 0.48, 95% CI 0.25-0.92; p = 0.03). CONCLUSIONS: A diffuse phenotype on MRI seems to be associated with shorter survival times in patients with CNS WHO grade 2 and 3 astrocytomas. These findings warrant further investigation in prospective data sets.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Weller J, Harba D, Kuschel L, et al. Association of a diffuse phenotype on MRI with shorter overall survival in patients with astrocytoma CNS WHO grades 2 and 3. J Neurosurg. 2026. PMID: 41616295. doi:10.3171/2025.9.JNS251254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。